Aclaris Therapeutics, Inc.
ACRS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001557746
No open-market purchases or sales by Aclaris Therapeutics, Inc. insiders were filed in the last 90 days; 148 institutions reported holding it in 13F filings for Q2 2026, worth $630.0M in total; no superinvestor holds it.
Q4 2025 vs. Q3 2025
How the institutions holding Aclaris Therapeutics, Inc. changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Q4 2025 | Change |
|---|---|---|---|
| Holders | 103 | 122 | +19 |
| Shares | 85.7M | 83.7M | −1.94M (−2.3%) |
| Value | $162.8M | $252.1M | +$89.3M (+54.8%) |
New holders (25)
Institutions that held Aclaris Therapeutics, Inc. at the end of Q4 2025 but not at the end of Q3 2025.
Sold out (6)
Institutions that held Aclaris Therapeutics, Inc. at the end of Q3 2025 and filed for Q4 2025 without it.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Stonepine Capital Management, LLC | 192,900 | $366.5K |
| Algert Global LLC | 65,630 | $124.7K |
| Oxford Asset Management LLP | 36,351 | $69.1K |
| Velan Capital Investment Management LP | 32,700 | $62.1K |
| Engineers Gate Manager LP | 17,844 | $33.9K |
| Clearstead Advisors, LLC | 1 | $2 |